Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Daratumumab, carfilzomib, and...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Bibliographic Details
Main Authors: Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas, Maria-Victoria Mateos, Hans Salwender, Paula Rodriguez-Otero, Cyrille Hulin, Lionel Karlin, Anna Sureda Balari, Joan Bargay, Lotfi Benboubker, Laura Rosiñol, Stefano Tarantolo, Howard Terebelo, Shiyi Yang, Jianping Wang, Ivo Nnane, Ming Qi, Michele Kosh, Maria Delioukina, Hartmut Goldschmidt
Format: Article
Language:English
Published: Nature Publishing Group 2023-03-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00805-x
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1038/s41408-023-00805-x

Similar Items

  • Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study
    by: Cyrille Hulin, et al.
    Published: (2024-08-01)
  • BELARUSIAN PROJECT “ASTROBLOKNOT” (ASTRONOMICAL NOTEBOOK) AND DATA MINING: RESULTS OBTAINED IN THE CONSTELLATION OF EQUULEUS
    by: Ivan Sergey, et al.
    Published: (2013-11-01)
  • S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
    by: C. Touzeau, et al.
    Published: (2022-06-01)
  • Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
    by: I. Vaxman, et al.
    Published: (2023-05-01)
  • Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    by: Yi L, et al.
    Published: (2024-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs